PT - JOURNAL ARTICLE AU - Eskandarian, Rahimeh AU - Sani, Zahra Alizadeh AU - Behjati, Mohaddeseh AU - Zahmatkesh, Mehrdad AU - Haddadi, Azadeh AU - Kakhi, Kourosh AU - Roshanzamir, Mohamad AU - Shoeibi, Afshin AU - Alizadehsani, Roohallah AU - Hussain, Sadiq AU - Khozeimeh, Fahime AU - Keyvani, Vahideh AU - Khosravi, Abbas AU - Nahavandi, Saeid AU - Shariful Islam, Sheikh Mohammed TI - Identification of clinical features associated with mortality in COVID-19 patients AID - 10.1101/2021.04.19.21255715 DP - 2021 Jan 01 TA - medRxiv PG - 2021.04.19.21255715 4099 - http://medrxiv.org/content/early/2021/04/20/2021.04.19.21255715.short 4100 - http://medrxiv.org/content/early/2021/04/20/2021.04.19.21255715.full AB - Background To prevent infectious diseases, it is necessary to understand how they are spread and their clinical features. Early identification of risk factors and clinical features is needed to identify critically ill patients, provide suitable treatments, and prevent mortality.Methods We conducted a prospective study on COVID-19 patients referred to a tertiary hospital in Iran between March and November 2020. Of the 3008 patients (mean age 59.3±18.7 years, range 1 to 100 years), 1324 were women. We investigated COVID-19 related mortality and its association with clinical features including headache, chest pain, symptoms on CT, hospitalization, time to infection, history of neurological disorders, having a single or multiple risk factors, fever, myalgia, dizziness, seizure, abdominal pain, nausea, vomiting, diarrhoea and anorexia.Findings There was a significant association between COVID-19 mortality and old age, headache, chest pain, respiratory distress, low respiratory rate, oxygen saturation less than 93%, need for a mechanical ventilator, having symptoms on CT, hospitalization, time to infection, history of hypertension, neurological disorders, cardiovascular diseases and having a risk factor or multiple risk factors. In contrast, there was no significant association between mortality and gender, fever, myalgia, dizziness, seizure, abdominal pain, nausea, vomiting, diarrhoea and anorexia.Interpretation Our results might help identify early symptoms related to COVID-19 and better manage patients clinically.Competing Interest StatementThe authors have declared no competing interest.Funding Statementthere is no external fundingAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was approved by the Omid Hospital Ethics Committee.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data that support the findings of this study are available on request from the corresponding author.